EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin



Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin



Thrombosis and Haemostasis 72(3): 381-386



The inhibitory effects of argatroban on clot- or fibrin-bound human thrombin were studied using the thrombin-specific chromogenic substrate S2238 (200 mu-M). These effects were compared to those of recombinant hirudin (rHV2 Lys 47) and the heparin/antithrombin III complex.

(PDF emailed within 1 workday: $29.90)

Accession: 008584351

Download citation: RISBibTeXText

PMID: 7855788



Related references

Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma. Blood Coagulation & Fibrinolysis 5(6): 879-887, 1994

Inhibition of clot-bound and free by a novel synthetic thrombin inhibitor , recombinant hirudin and heparin in human plasma. Blood Coagulation & Fibrinolysis 5(6): 879-887, 1994

Inhibition by Argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin. Thrombosis and Haemostasis 75(1): 154-160, 1996

Inhibition of extrinsic and intrinsic thrombin generation by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma. Blood Coagulation & Fibrinolysis 6(6): 553-560, 1995

Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 79(3): 657-665, 1989

Inhibition of fluid phase and clot-bound thrombin by the thrombin exosite I ligand LU 58463: comparison with heparin and hirudin. Haematologica 87(10): 1116-1117, 2002

Effect of heparin, hirudin, and a synthetic thrombin inhibitor on antithrombin III in thrombin-induced disseminated intravascular coagulation in rats. Haemostasis 17(6): 321-328, 1987

Platelet activation by clot-associated thrombin Inhibition by argatroban, a specific thrombin inhibitor. British Journal of Pharmacology 114(PROC SUPPL ): 122P, 1994

Pharmacological effects of a novel recombinant hirudin, CX-397, in vivo and in vitro: comparison with recombinant hirudin variant-1, heparin, and argatroban. Thrombosis and Haemostasis 81(2): 250-255, 1999

Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor. British Journal of Haematology 82(3): 627-629, 1992

Binding of fibrin monomer and heparin to thrombin in a ternary complex alters the environment of the thrombin catalytic site, reduces affinity for hirudin, and inhibits cleavage of fibrinogen. Journal of Biological Chemistry 271(42): 26088-26095, 1996

BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban. Thrombosis and Haemostasis 79(2): 431-438, 1998

BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent rodent models of arterial and venous thrombosis- Comparisons with heparin, r-hirudin, hirulong, inogatran and argatroban. Thrombosis & Haemostasis 79(2): 431-438, 1998

Structural and functional properties of human a-thrombin, phosphopyridoxylated a-thrombin, and cT-thrombin. Identification of lysyl residues in a-thrombin that are critical for heparin and fibrin(ogen) interactions. The Journal of Biological Chemistry 264: 419-25, 1989